From what OP said, I doubt they'd be able to keep up with the additional load of patient care (admittance especially) so there could be long wait times. At som

From what OP said, I doubt they'd be able to keep up with the additional load of patient care (admittance especially) so there could be long wait times. At some point, capabilities like this mature on the science end but are slowed down on technology (scaled manufacturing). That would take significant investment by a big pharma or a new venture-backed investment to go after things like this. Fingers cross this happens within my lifetime. From the article: >“This is a tremendously complicated manufacturing process,” says Joseph Fraietta, who designs T-cell cancer therapies at the University of Pennsylvania in Philadelphia. In some cases, the entire procedure took more than a year.